Living with polycythemia vera (PV) can leave patients feeling isolated, often wishing they’d better communicated their symptoms’ impact on daily life. Patient Power consulted three experts for guidance on preparing for medical visits and advocating for care needs.
Jodi Taub, a psychotherapist with 30 years of experience in chronic illness, advises patients to keep an updated record of medications, medical conditions, and healthcare providers. Dr. Natalie Rafaeli, a medical oncologist, suggests noting symptoms like fatigue, itching, headaches, dizziness, night sweats, and changes in exercise tolerance, along with questions for the doctor. These details can provide a clearer picture of the patient’s health status and help physicians tailor their approach.
Preparing for Your Appointment
Advance preparation can make patients feel more organized and less overwhelmed during appointments. Taub recommends bringing a trusted companion for support and note-taking, emphasizing their role in helping patients remember key points discussed. Dr. Rafaeli highlights that patients don’t need a perfect medical journal but should focus on describing changes and how they feel, as this provides valuable context beyond lab results.
When describing symptoms like fatigue and itching, Taub suggests answering specific questions: when they started, frequency, triggers, and impact on daily activities. A 0-to-10 severity scale with concrete examples can help communicate the symptoms’ effect on quality of life. For instance, explaining that fatigue requires lying down after a shower offers more insight than simply stating, “I’m very tired.”
Describing Symptoms and Managing Anxiety
Patients should not assume they must endure fatigue and itching, as treatment options may be available. If symptoms are dismissed, Taub advises patients to assertively ensure their concerns are understood by saying, “Before we move on, I want to make sure my concern is understood.” Dr. Rafaeli recommends requesting a referral to a hematologist or hematologist-oncologist if the current provider lacks PV expertise, as specialized care is key for managing this rare condition.
Medical anxiety can hinder communication during appointments. Taub suggests grounding techniques, deep breathing, and practicing conversations in advance to help patients remain present and articulate their needs. These strategies can reduce distress and improve the effectiveness of doctor-patient interactions.
Understanding pathology reports is key for PV patients. Dr. Olga Pozdnyakova, a hematopathologist, highlights key findings in bone marrow biopsies, including cellularity, panmyelosis, megakaryocytes, and fibrosis grade. These provide insights into disease progression and help distinguish PV from other myeloproliferative neoplasms (MPNs). Additionally, reports may include complete blood count (CBC), erythropoietin levels, and genetic testing results, all of which contribute to a full diagnosis.
Genetic testing plays a significant role in PV diagnosis. Dr. Pozdnyakova explains tests for JAK2 variants, which are present in 95-97% of PV cases. Next-generation sequencing and chromosome testing further refine diagnosis and prognosis, offering a more detailed understanding of the disease’s genetic underpinnings.
Managing Medical Anxiety and Grounding Techniques
Past healthcare experiences can shape how patients respond during appointments. Taub explains that repeated procedures, uncertainty, or feeling dismissed can contribute to heightened distress in medical settings. This anxiety can manifest as difficulty processing information, finding words, or physical symptoms like a racing heart, making it harder to engage effectively with providers.
Genetic Testing and Pathology Report Reliability
Genetic testing plays a key role in PV diagnosis. Dr. Pozdnyakova outlines four key tests: JAK2 V617F testing, JAK2 exon 12 testing, next-generation sequencing panels, and chromosome testing (karyotyping). JAK2 V617F testing identifies the variant present in 95-97% of PV cases, while JAK2 exon 12 testing covers most remaining cases. Next-generation sequencing provides prognostic information, and karyotyping helps rule out other MPNs.
Dr. Pozdnyakova notes that bone marrow findings can vary depending on the interpreter. However, she emphasizes that this doesn’t undermine the diagnosis. An experienced hematopathologist should examine megakaryocytes to differentiate PV from other MPNs, ensuring accurate and reliable results.
If advocating for yourself feels difficult, consider bringing a trusted loved one to appointments or working with a patient advocate experienced in blood cancers or rare diseases. These individuals can provide emotional support, help articulate concerns, and ensure that the patient’s voice is heard. By leveraging these resources, patients can handle their care journey with greater confidence and clarity.